Abstract:Abstract Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanism of apatinib on NSCLC remains unclear. Methods MTT, EdU, AO/EB staining, TUNEL staining, flow cytometry, colony formation assays were performed to investigate the effects of apatinib on cell proliferation, cell cycle distribution, apoptosis and cancer stem like properties. Wound healing and transwell assays were conducted to explore the role of apatinib on migration and invasion. The regulation of apatinib on VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling were detected. Furthermore, we collected conditioned medium (CM) from A549 and H1299 cells to stimulate phorbol myristate acetate (PMA)-activated THP-1 cells, and examined the effect of apatinib on PD-L1 expression in macrophages. The Jurkat T cells and NSCLC cells co-culture model was used to assess the effect of apatinib on T cells activation. Subcutaneous tumor formation models were established to evaluate the effects of apatinib in vivo. Histochemical, immunohistochemical staining and ELISA assay were used to examine the levels of signaling molecules in tumors. Results We showed that apatinib inhibited cell proliferation and promoted apoptosis in NSCLC cells in vitro. Apatinib induced cell cycle arrest at G1 phase and suppressed the expression of Cyclin D1 and CDK4. Moreover, apatinib upregulated Cleaved Caspase 3, Cleaved Caspase 9 and Bax, and downregulated Bcl-2 in NSCLC cells. The colony formation ability and the number of CD133 positive cells were significantly decreased by apatinib, suggesting that apatinib inhibited the malignant and stem-like features of NSCLC cells. Mechanistically, apatinib inhibited PD-L1 and c-Myc expression by targeting VEGFR2/STAT3 signaling. Apatinib also inhibited PD-L1 expression in THP-1 derived macrophages stimulated by CM from NSCLC cells. Furthermore, apatinib pretreatment increased CD69 expression and IFN-γ secretion in stimulated Jurkat T cells co-cultured with NSCLC cells. Apatinib also promoted ROS production and inhibited Nrf2 and p62 expression, leading to the autophagic and apoptotic cell death in NSCLC. Moreover, apatinib significantly inhibited tumor growth in vivo. Conclusion Our data indicated that apatinib induced autophagy and apoptosis in NSCLC via regulating VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling.

The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer‐bearing mice and patients

Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31

Apatinib Enhances Chemosensitivity of ABT-199 in Diffuse Large B-cell Lymphoma

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Apatinib has anti-tumor effects and induces autophagy in lung cancer cells with high expression of VEGFR-2

The Efficacy and Safety of Apatinib in the Treatment of Advanced Non-Small Cell Lung Cancer: A Retrospective Trial

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450.

Effects of Apatinib on the "Stemness" of Non-Small-Cell Lung Cancer Cells In Vivo and Its Related Mechanisms

The inhibitory effect of Apatinib on the growth of triple negative breast cancer cell line MDA-MB-231 in vitro

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and -Catenin Signaling

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Apatinib Inhibits Pancreatic Cancer Growth, Migration and Invasion Through the PI3K/AKT and ERK1/2/MAPK Pathways.

Efficacy, Safety and Predictive Indicators of Apatinib after Multilines Treatment in Advanced Nonsquamous Nonsmall Cell Lung Cancer: Apatinib Treatment in Nonsquamous NSCLC.

A Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment Regimens.

Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis.

Apatinib is Effective for Treatment of Advanced Hepatocellular Carcinoma.

The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer

Effect of Apatinib on Serum CD4+CD25+ T cells, NK Cells, and T Cells Subgroup in Malignant Tumor

Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer